The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer

被引：5
作者：
Pharaon, Rebecca R. [1 ]
Xing, Yan [1 ]
Agulnik, Mark [1 ]
Villaflor, Victoria M. [1 ]
机构：
[1] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA
来源：
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词：
immunotherapy; head and neck cancer; oropharyngeal squamous cell carcinoma; nasopharyngeal carcinoma; viral-associated cancers; human papillomavirus; Epstein-Barr virus; SQUAMOUS-CELL CARCINOMA; EPSTEIN-BARR-VIRUS; PHASE-II TRIAL; HUMAN-PAPILLOMAVIRUS; NASOPHARYNGEAL CARCINOMA; OPEN-LABEL; OROPHARYNGEAL CANCER; ANTITUMOR-ACTIVITY; METASTATIC HEAD; PLUS CETUXIMAB;
D O I：
10.3389/fonc.2021.649963
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A subset of head and neck cancers arising in the oropharynx and the nasopharynx are associated with human papillomavirus or Epstein-Barr virus. Unfortunately, limited treatment options exist once patients develop recurrent or metastatic disease in these cancers. Interest has risen in utilizing novel strategies including combination immune checkpoint inhibitors, vaccines, and adoptive cellular therapy, to improve treatment response and outcomes. Several ongoing studies are investigating the potential to overcome resistance to standard of care chemoradiation therapy with monotherapy or combination immunotherapy strategies in these viral-associated head and neck cancers.
引用
收藏
页数：12
相关论文
共 50 条
  • [21] Biomarkers for immunotherapy response in head and neck cancer
    Gavrielatou, Niki
    Doumas, Stergios
    Economopoulou, Panagiota
    Foukas, Periklis G.
    Psyrri, Amanda
    CANCER TREATMENT REVIEWS, 2020, 84
  • [22] The role of surgery for HPV-associated head and neck cancer
    Mydlarz, Wojciech K.
    Chan, Jason Y. K.
    Richmon, Jeremy D.
    ORAL ONCOLOGY, 2015, 51 (04) : 305 - 313
  • [23] Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer
    Le, Xiuning
    Ferrarotto, Renata
    Wise-Draper, Trisha
    Gillison, Maura
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (07): : 899 - 906
  • [24] Immunotherapy of Head and Neck Cancer: Emerging Clinical Trials From a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting
    Bauman, Julie E.
    Cohen, Ezra
    Ferris, Robert L.
    Adelstein, David J.
    Brizel, David M.
    Ridge, John A.
    O'Sullivan, Brian
    Burtness, Barbara A.
    Butterfield, Lisa H.
    Carson, William E.
    Disis, Mary L.
    Fox, Bernard A.
    Gajewski, Thomas F.
    Gillison, Maura L.
    Hodge, James W.
    Quynh-Thu Le
    Raben, David
    Strome, Scott E.
    Lynn, Jean
    Malik, Shakun
    CANCER, 2017, 123 (07) : 1259 - 1271
  • [25] EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy
    Kang, James J.
    Ko, Albert
    Kil, Sang Hoon
    Clair, Jon Mallen-St.
    Shin, Daniel Sanghoon
    Wang, Marilene B.
    Srivatsan, Eri S.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (01):
  • [26] Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review
    Guidi, Alessandro
    Codeca, Carla
    Ferrari, Daris
    MEDICAL ONCOLOGY, 2018, 35 (03)
  • [27] Immunotherapy in head and neck cancer: aiming at EXTREME precision
    Szturz, Petr
    Vermorken, Jan B.
    BMC MEDICINE, 2017, 15
  • [28] Human papilloma virus associated head and neck cancer: A PCR based study
    Barwad, Adarsh
    Sood, Swati
    Gupta, Nalini
    Rajwanshi, Arvind
    Panda, Naresh
    Srinivasan, Radhika
    DIAGNOSTIC CYTOPATHOLOGY, 2012, 40 (10) : 893 - 897
  • [29] Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review)
    Wei, Chun
    Lan, Xiaojun
    Qiu, Maona
    Cui, Ran
    Fu, Qiuxia
    Shinge, Shafiu A. Umar
    Muluh, Tobias Achu
    Jiang, Ou
    ONCOLOGY LETTERS, 2023, 26 (03)
  • [30] HPV Associated Head and Neck Cancer
    Spence, Tara
    Bruce, Jeff
    Yip, Kenneth W.
    Liu, Fei-Fei
    CANCERS, 2016, 8 (08)
12345